linjc16/ctgov huggingface dataset:
Anterolateral Versus Posterolateral Approach to the Fractured Hip Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the anterolateral in comparison to posterolateral approach to the hip arthroplasty gives an equal or better clinical results.

Detailed Description
-----------------
The purpose of this study is to compare the anterolateral- to posterolateral approaches in patients suffering a displaced femoral neck fracture operated with an hip arthroplasty. Our hypothesis is that the anterolateral approach gives equal or better clinical function, health related quality of life and less complication and reoperations.

Official Title
-----------------
Anterolateral Versus Posterolateral Approach to the Fractured Hip Arthroplasty - a Change in Approach at Sundsvall Hospital.

Conditions
-----------------
Femoral Neck Fracture

Intervention / Treatment
-----------------
* Procedure: Anterolateral approach


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 65 years Displaced femoral neck fracture Exclusion Criteria: Pathologic fracture Not Swedish speaker Not living in Västernorrlands county

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Anterolateral approach<br>Patients with a displaced femoral neck fracture operated through the anterolateral approach to the hip arthroplasty. Lubinus total hip arthroplasty or varikopf hemiarthroplasty. | Procedure: Anterolateral approach<br>* Anterolateral approach acording to Gammer for hip arthroplasty.<br>* Other names: Lubinus total hip arthroplasty or varikopf hemiarthroplasty.;|
| No Intervention: Posterolateral approach<br>Patients with a displaced femoral neck fracture operated through the posterolateral approach to the hip arthroplasty. Lubinus total hip arthroplasty or varikopf hemiarthroplasty. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Womac |  | 1 year postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EQ5D |  | 1 year postoperatively | 
| Harris Hip Score |  | 1 year postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
femoral neck fracture, arthroplasty, surgical approach, anterolateral, posterolateral
Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents

Study Overview
=================
Brief Summary
-----------------
The study is designed to evaluate the increment of serum 25 (OH) vitamin D levels in normal weight adolescents following a 12-week supplementation with Vitamin D3 2000 IU/day.

Detailed Description
-----------------
Twenty normal weight adolescents between ages 12-18 that are age and gender would receive vitamin D3 supplementation at a dose of 2000 IU/day. Levels of 25(OH)vitamin D would be measured at baseline and after 12 weeks.Relationship between 25 OH vitamin D levels and other demographic variables will be assessed.The primary endpoint in this study is the 25 OH Vitamin D level at 12 weeks.

Official Title
-----------------
A Pilot Study to Evaluate the Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents

Conditions
-----------------
Vitamin D Deficiency

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamin D3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Subjects between ages 12 and 18 years with BMI between the 5th and the 85th percentile for age and gender. Exclusion Criteria: Subjects with 25 (OH)- D levels >80 ng/mL Serum calcium >10.8 mg/dL Serum phosphorus > 5.5 mg/dl Pregnancy or nursing Current cancer Patients on multivitamin supplementation Dietary calcium intake exceeding 1500 mg/day Hepatic or renal disorders Type 1 or Type 2 diabetes mellitus Those receiving insulin, metformin, or oral hypoglycemic medications Malabsorption disorders (Celiac disease, Cystic fibrosis, Inflammatory bowel disease)

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin D3<br>Patients would receive 2000 IU of vitamin D3 daily for 12 weeks | Dietary Supplement: Vitamin D3<br>* 2000 IU orally once daily for 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increment in 25(OH)vitamin D level |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum Calcium |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitamin D, Supplementation, Adolescence
Resistance Training in Elderly

Study Overview
=================
Brief Summary
-----------------
In the present study the investigators aim to determine whether protein supplementation can augment the response to a 12 week resistance training program in healthy elderly men.

Official Title
-----------------
The Influence of Resistance Training on Body Composition and Muscle Characteristics in Healthy Elderly

Conditions
-----------------
Sarcopenia, Atrophy, Aging

Intervention / Treatment
-----------------
* Dietary Supplement: protein drink
* Behavioral: Resistance training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Living independently Exclusion Criteria: Diabetes Cardiovascular disease Orthopedic limitations Any disorder known to compromise ability for resistance training History of resistance training in past 5 years

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>placebo drink | Behavioral: Resistance training<br>* 12 weeks resistance training, 3 days per week<br>|
| Experimental: 2<br>protein drink | Dietary Supplement: protein drink<br>* 250 ml protein hydrolysate solution<br>Behavioral: Resistance training<br>* 12 weeks resistance training, 3 days per week<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle mass measured at limb and cellular level |  | before and after 12 weeks of intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle strength |  | before and after 12 weeks of intervention | 
| Body composition |  | before and after 12 weeks of intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
resistance training, protein supplementation, hypertrophy
Polyphenols and Endothelial Function

Study Overview
=================
Brief Summary
-----------------
To determine whether fruit juice rich in polyphenols might increase exercise capacity and memory in healthy sedentary subjects.Both parameters might be improved because of the anti-oxidant effects of polyphenols.

Official Title
-----------------
Polyphenols Rich Fruit Juice Effects on Endothelial Function and Exercise Capacity

Conditions
-----------------
Sedentary Subjects

Intervention / Treatment
-----------------
* Dietary Supplement: juice rich in polyphenols
* Dietary Supplement: juice poor in polyphenols


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sedentary Exclusion Criteria: diabetes

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Dietary Supplement: juice rich in polyphenols<br>* juice during 2 weeks<br>|
| Placebo Comparator: 2<br> | Dietary Supplement: juice poor in polyphenols<br>* juice during 2 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Flow-mediated dilatation |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise, capacity memory |  | 2 years |
Dynamic Arterial Elastance During General Anesthesia Induction

Study Overview
=================
Brief Summary
-----------------
This study evaluates if dynamic arterial elastance measured before general anesthesia induction can predict the occurrence of hypotension due to general anesthesia induction.

Detailed Description
-----------------
As general anesthetics may be responsible for vasodilation and cardiac depression, arterial hypotension after induction of general anesthesia is a common event and may contribute to an adverse outcome. Dynamic arterial elastance has been proposed as a functional parameter of arterial tone and studies showed that it was able to predict pressure response to fluid administration in fluid-responsive patients and the amount of mean arterial pressure riduction as a conseguence of noradrenaline dose reduction in critically ill patients.

Official Title
-----------------
Dynamic Arterial Elastance as Predictive Parameter of Hypotension During General Anesthesia Induction.

Conditions
-----------------
Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that will be undergone to general anesthesia for surgery Patients that need mini-invasive cardiac output monitoring during surgery Exclusion Criteria: Age <18 yo Pregnancy Arrhythmia Severe valvular diseases Uncorrectable alterations of arterial signal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Baseline value of Eadyn as predictor of hypotension occurrence due to general anesthesia induction | Dynamic arterial elastance (Eadyn) will be recorded at baseline before induction of general anesthesia. Mean arterial pressure (MAP) will be recorded at baseline and continuously until tracheal intubation. The lowest value of MAP will be considered to define hypotension occurrence. | From baseline (before general anesthesia induction) up to 30 minutes. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between Eadyn and severity of hypotension due to anesthesia induction | To evaluate the correlation between the baseline value of Eadyn and the severity of hypotension when it will occur after induction of general anesthesia | From baseline (before general anesthesia induction) up to 30 minutes. |
Interest of Nitazoxanide Treatment of Enterocytozoon Bieneusi Intestinal Microsporidiosis

Study Overview
=================
Brief Summary
-----------------
Microsporidia are pathogenic fungi mainly responsible for profuse watery diarrhea, requiring management in immunocompromised patients. The main immunocompromised population affected by these infections consists of solid organ transplant recipients (SOT), mainly kidney ( 70% of cases in immunocompromised patients). In this population, the infection is severe, and becomes chronic in the absence of appropriate care, the species Enterocytozoon bieneusi being found in more than 95% of these cases. Reducing immunosuppression (adjustment of immunosuppressive therapy) can sometimes be enough to eliminate the pathogen. However, in some cases, specific treatment is necessary. The only molecule whose efficacy has been proven to date to treat infections caused by E. bieneusi is fumagillin (FLISINT®), however its production has been stopped for almost 2 years. Due to the therapeutic impasse, the use of nitazoxanide (ALINIA®) to treat E. bieneusi microsporidiosis is becoming common, despite the lack of proof of its efficacy. It seems important and urgent to evaluate the relevance of the use of nitazoxanide, particularly in SOT, for the treatment of intestinal microsporidiosis due to E. bieneusi.

Official Title
-----------------
Interest of Nitazoxanide Treatment of Enterocytozoon Bieneusi Intestinal Microsporidiosis

Conditions
-----------------
Microsporidiosis Intestinal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: With a diagnosis of intestinal infection caused by E. bieneusi between 01/01/2018 and 03/31/2022 having received treatment with nitazoxanide (NITAZO group), or fumagillin (FUMA group), or albendazole (ABZ) or having received no specific treatment but having benefited from an adjustment of the doses of immunosuppressants (IS group) Exclusion Criteria: With a diagnosis of extraintestinal infection With a diagnosis of infection by a species other than E. bieneusi

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficiency by symptoms | time to resolution of symptoms | 1 year | 
| efficiency by parasitology | parasitological negativation | 1 year | 
| efficiency by relapses | number of relapses | 1 year | 
| tolerance of treatment | duration of treatment | 1 year | 
| tolerance with side effects | side effects during treatment: value of platelets, liver enzymes, occurrence of drug interactions | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microsporidia, Enterocytozoon bieneusi, solid organ transplant
Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of breast tissue in the laboratory may help doctors learn more about the genes and proteins found in breast tissue. PURPOSE: This phase I trial is studying genes and proteins in breast tissue from women undergoing surgery for breast cancer or core biopsy of the breast.

Detailed Description
-----------------
OBJECTIVES: Assess tumor gene expression information from women undergoing surgery for breast cancer or core biopsy sampling of the breast. OUTLINE: This is a pilot study. Tumor tissue is collected and analyzed for tumor gene expression by DNA microarray analysis for research studies. PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.

Official Title
-----------------
Pilot Study for Analysis of Tumor Gene Expression by DNA Microarray Analysis in Patients Undergoing Breast Cancer Surgery or Core Biopsy Sampling

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Genetic: microarray analysis
* Procedure: breast biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Undergoing surgery for breast cancer OR core biopsy sampling of the breast PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: microarray analysis|tumor specimen will be assessed by microarray analysis|
|Procedure: breast biopsy|A breast biopsy will be done to obtain a tumor specimen|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor Gene Expression as Assessed by RNA Microarray Analysis | Concentration of RNA recovered from breast needle biopsies | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer
LH Hormone Pulsation in the Luteal Phase in GnRH Antagonist IVF Cycles Triggered by GnRH Agonist for Final Oocyte Maturation

Study Overview
=================
Brief Summary
-----------------
Monitoring the LH pulsatility during the Luteal phase in GnRH antagonist IVF cycles triggered by GnRH agonist for final oocyte maturation.

Detailed Description
-----------------
About two decades ago the GnRH antagonist has been used in IVF cycles to prevent premature LH surge. In recent review GNRH antagonist has been found comparable to GnRH agonist in term of live birth rate but with reduced risk of OHSS. another advantage of using GnRH antagonist is the ability to use GnRH agonist for final oocyte maturation which has been shown to nearly eliminate the risk of OHSS. The exact mechanism of this risk reduction is still unknown. Our aim is to do a frequent blood tests every 20 minutes for 6 hours duration in the day of ovum pick up or the day of embryo transfer to measure the level of LH, estradiol and progesterone in women triggered with GnRH agonist for final oocyte maturation.

Official Title
-----------------
LH Hormone Pulsation in the Luteal Phase in GnRH Antagonist IVF Cycles Triggered by GnRH Agonist for Final Oocyte Maturation

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age: 18-42 years old BMI < 32 kg/m2 Exclusion Criteria: Hypogonadotropic hypogonadism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group 1<br>group 1 include 10 women in which blood tests will be taken on the day of oocyte pick up | |
| group 2<br>group 2 include 10 women in which blood tests will be taken on the day of embryo transfer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| luteinizing hormone pulsatility frequency |  | 6 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
luteinizing hormone pulsatility, estradiol level, progesterone level
The Utility of Platelet Rich Plasma in Hair Loss

Study Overview
=================
Brief Summary
-----------------
Platelet rich plasma (PRP) is an autologous preparation of human plasma with high concentration of platelets. Platelets release numerous growth factors, which stimulate cell proliferation and differentiation. The purpose of this research is to investigate the potential of PRP injection for treatment of hair loss. Clinical outcomes will be assessed by noninvasive techniques including dermoscopy, multiphoton microscopy, optical coherence tomography, optical Doppler tomography and multispectral imaging.

Official Title
-----------------
The Utility of Platelet Rich Plasma in Hair Loss

Conditions
-----------------
Androgenetic Alopecia

Intervention / Treatment
-----------------
* Procedure: Platelet rich plasma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years of age Ability to understand and carry out instructions Diagnosed with alopecia Exclusion Criteria: Inability to understand and.or carry out instructions Pregnant women Use of any topical medication (such as minoxidil or any other solution for hair growth), oral medication (finasteride, dutasteride, or antiandrogens), laser therapy, or chemotherapy, within the preceding 4 weeks. Personal medical history of bleeding disorders Personal medical history of platelet dysfunction syndrome Anti-coagulation therapy or nonsteroidal anti-inflammatory drugs in the last 1 week.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Prospective treatment<br> | Procedure: Platelet rich plasma<br>* Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hair density to measure the efficacy of treatment |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hair count (number of hairs/0.65 cm2) |  | 6 months | 
| Terminal hair density |  | 6 months | 
| Anagen hair percentage |  | 6 months | 
| Telogen hair percentage |  | 6 months | 
| Anagen/telogen ratio |  | After 3 and 6 months | 
| Changes in hair structure, diameter, and blood flow | As measured by optical coherence tomography | 6 months |